Trial Profile
International Multicenter Comparative Double Blind Study of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jul 2017
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Ankylosing spondylitis
- Focus Pharmacokinetics
- Acronyms ASART-1
- Sponsors Biocad
- 17 Jun 2017 Results of three clinical trials of infliximab biosimilar BCD-055 (ASART-1, ASART-2 and LIRA) including comparative data on pharmacokinetics (PK), efficacy and safety in a variety of patient populations, presented at the 18th Annual Congress of the European League Against Rheumatism.
- 03 May 2016 Time frame for primary endpoints has been changed from 28 weeks to 2 weeks.
- 03 May 2016 Status changed from active, no longer recruiting to completed.